Marksans Pharma Ltd
Marksans Pharma Ltd (MARKSANS) last traded at ₹318, a market capitalisation of ₹14,413 crore, on a P/E of 27.9. Over the past 52 weeks the stock has ranged between ₹155 and ₹346. Marksans Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹841 crore and net profit of ₹159 crore. The next scheduled event is a dividend on 27 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Marksans Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Marksans Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹841 cr, up 35.6% from ₹620 cr a year earlier. Net profit was ₹159 cr, up 174.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 642 | 682 | 708 | 620 | 720 | 754 | 856 | 841 |
| Expenses | 495 | 543 | 582 | 520 | 576 | 594 | 661 | 628 |
| Operating profit | 147 | 139 | 127 | 100 | 144 | 161 | 195 | 213 |
| OPM % | 23% | 20% | 18% | 16% | 20% | 21% | 23% | 25% |
| Other income | -0 | 28 | 15 | 6 | 22 | 20 | 35 | 25 |
| Interest | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 |
| Depreciation | 20 | 21 | 23 | 23 | 27 | 24 | 24 | 25 |
| Profit before tax | 125 | 143 | 116 | 77 | 133 | 151 | 200 | 207 |
| Tax % | 22% | 27% | 22% | 24% | 26% | 25% | 25% | 23% |
| Net profit | 98 | 105 | 91 | 58 | 99 | 114 | 149 | 159 |
| EPS (₹) | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Marksans Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 | 3,172 |
| Operating profit | 340 | 259 | 340 | 459 | 533 | 601 | 714 |
| OPM % | 25% | 17% | 18% | 21% | 20% | 20% | 22% |
| Net profit | 239 | 187 | 265 | 315 | 383 | 420 | 521 |
| EPS (₹) | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 9.22 | 11.41 |
TTM is the trailing twelve months to the most recent quarter.
Marksans Pharma Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 16%
- 3 Years
- 17%
- TTM
- 20%
- 10 Years
- 18%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 48%
- 10 Years
- 23%
- 5 Years
- 35%
- 3 Years
- 43%
- 1 Year
- 82%
- 10 Years
- 17%
- 5 Years
- 17%
- 3 Years
- 16%
- Last Year
- 15%
Marksans Pharma Ltd shareholding pattern
Promoters held 43.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 17.47% and DIIs 6.19%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FIIs | 21.31% | 21.95% | 22.19% | 19.89% | 16.92% | 8.13% | 16.76% | 17.47% |
| DIIs | 4.10% | 4.30% | 4.55% | 5.50% | 5.28% | 5.91% | 6.57% | 6.19% |
| Public | 30.70% | 29.88% | 29.37% | 30.74% | 33.93% | 42.08% | 32.78% | 32.46% |
| No. of shareholders | 2,48,845 | 2,59,813 | 2,57,273 | 2,56,221 | 2,65,788 | 2,55,153 | 2,46,279 | 2,46,635 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Marksans Pharma Ltd
Upcoming Marksans Pharma Ltd events
The next scheduled event is a dividend on 27 Aug 2026.
- DividendShareholder approval for final dividend of INR 0.90 per share and re-appointment of directors at 34th AGM.
- AGM34th Annual General Meeting
See the full results calendar for every Indian company reporting in the next 30 days.
Marksans Pharma Ltd corporate filings
- Transcript of Investors/Analyst meet on Q1 FY 27 Financial ResultsCompany Updatehigh impact
Cruxal's analysis: Marksans Pharma delivered a robust Q1 FY27 performance, reporting revenue of INR841 crore…
Read the full analysis - Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial ResultsCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd. has formally complied with SEBI disclosure requirements by uploading…
Read the full analysis - Newspaper Publication for Unaudited Financial Results for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Marksans Pharma Ltd. has released its unaudited financial results for the quarter ended…
Read the full analysis - Press Release for Financial Results Q1 FY 27Company Updatehigh impact
Cruxal's analysis: Marksans Pharma Ltd. delivered a robust performance for Q1FY27, with operating revenue…
Read the full analysis - Investor Presentation Q1 FY 27Company Updatehigh impact
Cruxal's analysis: Marksans Pharma Limited delivered a robust performance in Q1 FY27, reporting revenue of…
Read the full analysis - The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026Board Meetinghigh impact
Cruxal's analysis: Marksans Pharma Limited delivered a robust performance for the quarter ended 30 June…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd has fulfilled regulatory requirements under Regulation 30 of the SEBI…
Read the full analysis - Business Responsibility and Sustainability Reporting (BRSR)Otherslow impact
Cruxal's analysis: Marksans Pharma Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Reg. 34 (1) Annual Report.Otherslow impact
Cruxal's analysis: Marksans Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26 to the…
Read the full analysis - Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026AGM/EGMmedium impact
Cruxal's analysis: Marksans Pharma Ltd. has announced its 34th Annual General Meeting (AGM) to be held on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Marksans Pharma Ltd
Cruxal reads every Marksans Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.